Page last updated: 2024-08-24

ruthenium chloride (rucl3) and rifampin

ruthenium chloride (rucl3) has been researched along with rifampin in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Li, K; Li, W; Liang, L; Long, D; Zeng, J; Zhao, Y1

Other Studies

1 other study(ies) available for ruthenium chloride (rucl3) and rifampin

ArticleYear
A coordinated ruthenium-rifampicin complex reprogramming the colon carcinoma micro-environment mediated by modulation of p53/AkT/mTOR/VEGF pathway.
    Toxicology and applied pharmacology, 2021, 09-01, Volume: 426

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Colon; Colonic Neoplasms; Drug Combinations; Female; HCT116 Cells; HT29 Cells; Humans; Male; Mice, Inbred BALB C; Proto-Oncogene Proteins c-akt; Rats, Wistar; Rifampin; Ruthenium Compounds; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Microenvironment; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A

2021